A number of equity research firms have modified their stock ratings and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last week:
Edwards Lifesciences had its price target lowered by analysts at Goldman Sachs to $86.00.
Edwards Lifesciences was given a reiterated “buy” by analysts at Jefferies. The analysts now have a $92.00 price target on the stock.
Edwards Lifesciences was given a reiterated “overweight” by analysts at Piper Jaffray. The analysts now have a $83.00 price target on the stock.
Edwards Lifesciences was upgraded by analysts at Lazard Capital from a “neutral” rating to a “buy” rating.
Edwards Lifesciences was given a reiterated “market perform” by analysts at Rodman & Renshaw.
About Edwards Lifesciences:
Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat advanced cardiovascular disease. The Company is focused specifically on technologies that treat structural heart disease and critically ill patients. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease are categorized into four areas: Heart Valve Therapy, Critical Care, Cardiac Surgery Systems and Vascular. The Company operates in United States, Europe, Japan and others. In March 2011, the Company completed the acquisition of Embrella Cardiovascular, Inc. During year ended December 31, 2010, the Company discontinued its MONARC transcatheter mitral valve program
Shares of Edwards Lifesciences opened at 63.02 on Friday. Edwards Lifesciences has a 52 week low of $61.63 and a 52 week high of $91.82. The stock’s 50-day moving average is $73.01 and its 200-day moving average is $81.1. The company has a market cap of $7.189 billion and a price-to-earnings ratio of 32.02.
